Real-World Treatment Study of Koselugo (Selumetinib)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-99
SponsorAstraZeneca
About this trial
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea.
This study will provide information on the Korean patient population that is treated with the study drug.
Eligibility criteria
Qualifiers
Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
Provision of signed and dated written informed consent by the patient or legally acceptable representative
Disqualifiers
Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
Provision of signed and dated written informed consent by the patient or legally acceptable representative
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov